The Enigma of Pharma Pricing
Success in innovation has lead to a market failure
Pharma companies are more productive than ever. Many of the new revolutionary cures for cancer, HepC etc, often come in the form of combination or sequential therapies. At list prices set by companies, these regimens are becoming prohibitively expensive in America, are already rationed in Europe and unavailable in emerging markets.
A marketplace that can handle the complexity of the future of pharmaceutical pricing
We solve this problem by creating a special kind of exchange –– secure virtual terminals that allow parties to explore hypothetical scenarios and exchange binding contingent commitments with each other.